Okla. Stat. tit. 63, § 63-5030.4A
This is the official text of Okla. Stat. tit. 63, § 63-5030.4A, part of Oklahoma’s Stat. tit. 63, — part of the compiled statutory law of Oklahoma, published by the state as "Stat. tit. 63,." Browse the sections below, each linked to its official government source.
Not legal advice. This page reproduces the official text of a government statute for reference only. Laws change, and how a statute applies depends on your specific facts. For advice about your situation, consult a licensed attorney in your state.
Disease state management programs – Feasibility study
Official statutory text
A. The Oklahoma Health Care Authority shall study the
feasibility of implementing one or more disease state management
programs.
B. The components of the study shall include, but not be
limited to:
1. A description and assessment of the findings, costs of the
program, savings incurred and estimated costs and savings of an
expansion of the pilot program for asthma disease state management
developed by the Authority;
2. An overview of disease state management programs for
enrollees of health management organizations contracting with the
Authority pursuant to the Sooner Care Plus Program;
3. An assessment of the adaptability of such disease state
management programs for the Medicaid fee-for-service population;
4. An overview of representative vendors of the disease state
management programs, including their characteristics, capabilities
and charges for products and services;
5. An overview and assessment of the disease state management
pilot project developed by the Oklahoma State Education Employees
Government Insurance Board; and
6. A record, if available, of the savings generated by disease
state management programs in other states by pharmaceutical
manufacturers for Medicaid fee-for-service recipients.
C. The study shall be under the joint direction of the Disease
State Management Director and the Pharmacy Director of the Oklahoma
Health Care Authority. The Directors shall consult with the
following entities as they deem necessary:
1. Medical, pharmacy, and nursing professionals who are
experienced in disease state management programs;
2. Appropriate pharmaceutical manufacturers in connection with
study components outlined in paragraphs 4 and 5 of subsection B of
this section;
3. Disease state management vendors; and
4. Other resources as necessary including, but not limited to,
health care advocates.
D. The Oklahoma Health Care Authority shall submit periodic
progress reports to the Joint Legislative Oversight Committee. The
Oklahoma Health Care Authority shall publish and submit a final
report by December 1, 2002, to the Speaker of the Oklahoma House of
Representatives, the President Pro Tempore of the Senate, the
Governor, and the chair of the Health and Social Services
Subcommittee of the Appropriation and Budget Committee of the
Oklahoma Statutes - Title 63. Public Health and Safety Page 1737
Oklahoma House of Representatives and of the Health and Social
Services Subcommittee of the Committee on Appropriations of the
Oklahoma State Senate.
E. As used in this section, "disease state management program"
means an integrated system of interventions, measurements and
refinements of health care delivery that include:
1. Patient education and involvement in self-care techniques;
2. Clinical policies/best practices that extend across the
entire continuum of care;
3. Outpatient drug management;
4. Clinical information systems with the capacity to identify,
classify, and track defined patient populations;
5. Informed support of physicians;
6. Team-oriented multidisciplinary approach; and
7. Feedback or continuous review.
feasibility of implementing one or more disease state management
programs.
B. The components of the study shall include, but not be
limited to:
1. A description and assessment of the findings, costs of the
program, savings incurred and estimated costs and savings of an
expansion of the pilot program for asthma disease state management
developed by the Authority;
2. An overview of disease state management programs for
enrollees of health management organizations contracting with the
Authority pursuant to the Sooner Care Plus Program;
3. An assessment of the adaptability of such disease state
management programs for the Medicaid fee-for-service population;
4. An overview of representative vendors of the disease state
management programs, including their characteristics, capabilities
and charges for products and services;
5. An overview and assessment of the disease state management
pilot project developed by the Oklahoma State Education Employees
Government Insurance Board; and
6. A record, if available, of the savings generated by disease
state management programs in other states by pharmaceutical
manufacturers for Medicaid fee-for-service recipients.
C. The study shall be under the joint direction of the Disease
State Management Director and the Pharmacy Director of the Oklahoma
Health Care Authority. The Directors shall consult with the
following entities as they deem necessary:
1. Medical, pharmacy, and nursing professionals who are
experienced in disease state management programs;
2. Appropriate pharmaceutical manufacturers in connection with
study components outlined in paragraphs 4 and 5 of subsection B of
this section;
3. Disease state management vendors; and
4. Other resources as necessary including, but not limited to,
health care advocates.
D. The Oklahoma Health Care Authority shall submit periodic
progress reports to the Joint Legislative Oversight Committee. The
Oklahoma Health Care Authority shall publish and submit a final
report by December 1, 2002, to the Speaker of the Oklahoma House of
Representatives, the President Pro Tempore of the Senate, the
Governor, and the chair of the Health and Social Services
Subcommittee of the Appropriation and Budget Committee of the
Oklahoma Statutes - Title 63. Public Health and Safety Page 1737
Oklahoma House of Representatives and of the Health and Social
Services Subcommittee of the Committee on Appropriations of the
Oklahoma State Senate.
E. As used in this section, "disease state management program"
means an integrated system of interventions, measurements and
refinements of health care delivery that include:
1. Patient education and involvement in self-care techniques;
2. Clinical policies/best practices that extend across the
entire continuum of care;
3. Outpatient drug management;
4. Clinical information systems with the capacity to identify,
classify, and track defined patient populations;
5. Informed support of physicians;
6. Team-oriented multidisciplinary approach; and
7. Feedback or continuous review.
Status: in_force · Read it on the official government site
Need a lawyer in Oklahoma?
Find a Oklahoma lawyer
About this page: Statute text is reproduced from official government publishers via the
Open US Law dataset
(Vaquill AI, snapshot v2026.08, CC BY 4.0). Primary legislative text like this is public domain under the government-edicts doctrine
(Georgia v. Public.Resource.Org, 2020). We link every section back to its official source so you can verify it independently.